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INTRODUCTION 
 
 
 
 
 
 
                                   INTRODUCTION  
 
 
Adenocarcinoma of the stomach was the leading cause of cancer-related death worldwide 
through most of the twentieth century. It now ranks second only to lung cancer, and an 
estimated 875,000 new cases are diagnosed annually worldwide. (1)   
The prognosis for this disease remains poor, except in a few countries. The explanations 
for these poor results are multifactorial. The lack of defined risk factors and specific 
symptoms and the relatively low incidence have contributed to the late stage at diagnosis 
seen in most Western countries. In Japan, where gastric cancer is endemic, more patients 
are diagnosed at an early stage, which is reflected by higher overall survival rates.  
Although the incidence of gastric cancer has decreased dramatically over the past century, 
the decline has been limited to cancers below the esophagogastric junction. The number of 
newly diagnosed cases of proximal gastric and esophagogastric junction adenocarcinomas 
has increased markedly since the mid-1980s(3,4). These tumors are thought to be 
biologically more aggressive than distal tumors and more complex to treat. In Indian 
subcontinent there are contrary reports that incidence has not decreased dramatically and 
there is no site specific change of adenocarcinoma of stomach. Male above 40 years still 
continue to be commonly affected (5).Gastric cancer is one of the ‘captains of men of 
death’    
The only proven, potentially curative treatment for gastric cancer is surgical resection of 
all gross and microscopic disease. Even after what is believed to be a "curative" 
gastrectomy, disease recurs in regional or distant sites, or both, in the majority of patients. 
Efforts to improve these poor results have focused on developing effective pre- and 
postoperative systemic and regional adjuvant therapies.  
Carcinoma Stomach is still leading killer in India as there is poor mass screening methods 
and usually late presentation. In potentially operable cases Surgery only offers probable 
cure and a good disease specific survival. 
Incidence of carcinoma stomach as with total no of cancer patients in Thanjavur Medical 
College and Hospital 
2005(July onwards)          : 86 / 709 cases 
2006         : 188 / 1641 cases                   
2007(upto August)       : 124 / 1130 cases 
TOTAL                            : 398 / 3480 cases 
Carcinoma stomach accounts to 11.4% of total cancer patients. 
It ranks third next to Breast and oral cavity malignancy. 
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AIMS OF STUDY 
 
To study various curative surgical modalities in the management of 
adenocarcinoma of stomach. 
 
To analyse patients undergoing curative resection (R0). 
 
To analyse age, sex, site, type, size, depth of invasion, nodes involved and 
examined in these patients. 
 
To study the extent of gastric resection and lymphadenectomy in these 
patients. 
  
To plot Nomogram for disease specific survival according to above factors. 
 
To study the mortality and morbidity in these patients. 
 
To compare and contrast with other studies. 
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REVIEW OF LITERATURE 
 
Epidemiology and Etiology  
The etiology of gastric cancer is likely multifactorial. A list of factors associated with 
increased risk of gastric adenocarcinoma is outlined in table. The etiologic basis for the 
rising incidence of proximal gastric and gastroesophageal junction cancers is being 
aggressively pursued. The increasing prevalence of obesity may be one contributing factor. 
Elevated body mass index and high caloric consumption have been associated with 
adenocarcinoma of the distal esophagus and gastric cardia. Gastroesophageal reflux disease 
may be another risk factor, although one also associated with obesity. A population-based, 
case-control study performed in Sweden found that for persons with recurrent symptoms of 
reflux, as compared to those without such symptoms, the odds ratio (OR) was 7.7 [95% 
confidence interval (CI), 5.3 to 11.4] for esophageal adenocarcinoma and 2.0 (95% CI, 1.4 
to 2.9) for developing adenocarcinoma of the gastric cardia.Other studies have found 
tobacco use to be associated with tumors at these sites. Gammon et al. observed an OR of 
2.4 (95% CI, 1.7 to 3.4) for the development of gastric cancer in cigarette smokers. 
Conversely, the use of aspirin and nonsteroidal and inflammatory drugs has been associated 
with a lower risk of esophageal and cardia cancers, implicating inflammation in the 
etiology of gastric cancer.  
 
In 1965, Lauren18 described two histologic types of gastric adenocarcinoma, intestinal and 
diffuse, which provided a model to understand better the etiology and epidemiology of the 
disease. The intestinal variant arises from precancerous lesions such as gastric atrophy or 
intestinal metaplasia within the stomach, occurs more commonly in men than in women, is 
more frequent in older people, and represents the dominant histologic type in regions where 
stomach cancer is endemic, suggesting a predominantly environmental etiology. The 
diffuse form does not typically arise from recognizable precancerous lesions. It is more 
common in low-incidence regions, occurs slightly more frequently in women and in 
younger patients, and has a higher association with familial occurrence (blood type A), 
suggesting a genetic etiology.19 Changes in the incidence of gastric cancer over time appear 
to reflect primarily a change in the incidence of the intestinal form.  
 
Gastric adenocarcinomas of the body and antrum of the stomach have a strong association 
with H pylori infection. This is a common infection in many parts of the world and was 
associated with a doubled risk of such cancers in a metaanalysis of multiple studies. The 
precise mechanism by which H pylori infection increases gastric cancer incidence is 
unclear, but it appears to increase the incidence of chronic atrophic gastritis, which 
produces a low-acidity environment, and the incidence of metaplasia and dysplasia. 
However, because H pylori infection is present in more than 50% of the population in 
many parts of the world, it is clearly not a sufficient event for the development of gastric 
cancer. Reports suggest that gastric cancer develops in 5% of H pylori–positive persons 
over 10 years. Multiple factors have been suggested that may interact with H pylori in 
producing gastric cancer, including tobacco use, age at infection, gender, and diet (e.g., low 
intake of ascorbic acid, carotene, and vitamin E). The precise type of H pylori infection 
may also be a factor. A number of studies have suggested that cagA strains, which are 
associated with cytotoxin expression, produce more gastric inflammation and have a strong 
association with gastric cancer.  
A number of other factors have been studied for their relationship with gastric cancer 
formation. Relatively little information is available to support a strong relationship between 
gastric cancer and alcohol use, although there may be a weak association between alcohol 
and tumors of the gastric cardia. A moderate association between tobacco use and gastric 
cancer formation appears to be present (overall risk, 1.5 to 2.5), with a long time interval 
after smoking cessation necessary before a decrease in risk is seen.  
 
Evidence is fairly strong that eating fruits and vegetables (especially when raw) has a 
protective effect against gastric cancer, and there is a suggestion that eating foods high in 
antioxidants, including vitamins C and E, carotenoids, and flavonoids, may be beneficial. 
Green tea, which contains large amounts of phenols, could also be protective, but results 
have been inconsistent. 
  
The data on nitrates found in preserved foods and gastric cancer are mixed. Nitrates can be 
converted to nitrites and then to N-nitroso compounds, which produce gastric cancer in 
laboratory animals. Some studies have shown a strong association between high intake of 
nitrates and gastric cancer, and other studies have shown no association. 
  
Radiation exposure, especially at a young age, has been shown to produce a high risk of 
gastric cancer. Gastric ulcer disease is also associated with an increased risk of gastric 
cancer, whereas duodenal ulcer disease is associated with a modest risk reduction. 
 
 
Anatomic Considerations  
The stomach begins at the gastroesophageal junction and ends at the pylorus. Above it lie 
the diaphragm and left lobe of the liver; before it is the abdominal wall; and below it are 
the transverse colon, mesocolon, and greater omentum. Behind and to the sides are the 
spleen, pancreas, left adrenal gland, left kidney, and splenic flexure of the colon. Cancers 
arising from the proximal greater curvature may directly involve the splenic hilum and tail 
of the pancreas, whereas more distal tumors may invade the transverse colon. Proximal 
cancers may extend into the diaphragm, spleen, or left lateral segment of the liver.  
 
The blood supply to the stomach is extensive and is based on vessels arising from the celiac 
axis. The right gastric artery, arising from the hepatic artery, and the left gastric artery, 
arising from the celiac axis directly, course along the lesser curvature. Along the greater 
curvature are the right gastroepiploic artery, which originates from the gastroduodenal 
artery at the inferior border of the proximal duodenum, and the left gastroepiploic artery, 
branching from the splenic artery laterally. The short gastric arteries (vasa brevia) arise 
directly from the splenic artery and make a relatively small contribution to the blood supply 
to the proximal portion of the stomach. The preservation of any of these vessels in the 
course of a subtotal gastrectomy for carcinoma is not necessary (and is not possible if the 
operation is performed correctly), and the most proximal few centimeters of remaining 
stomach are well supplied by collateral flow from the lower segmental esophageal arcade. 
The rich submucosal blood supply of the stomach is an important factor in its ability to heal 
rapidly and produce a low incidence of anastomotic disruption.  
The venous supply of the stomach tends to parallel the arterial supply. The venous efflux 
ultimately passes the portal venous system and is reflected in the fact that the liver is a 
primary site for distant metastatic spread.  
 
The lymphatic drainage of the stomach is extensive, and distinct anatomic groups of 
perigastric lymph nodes have been defined according to their relationship to the stomach 
and its blood supply. The six perigastric lymph node groups are the subpyloric and 
gastroepiploic nodes along the greater curvature and the suprapyloric and the lesser 
curvature lymph nodes along the lesser curvature and, proximally, the right and left 
pericardial nodes. The second echelon (extraperigastric) nodes include the common 
hepatic, left gastric, splenic hilum, and splenic artery lymphatics, which drain into the 
celiac and periaortic lymphatics. Proximally are the lower esophageal lymph nodes; 
extensive spread of gastric cancer along the intrathoracic lymph channels may be 
manifested clinically by a metastatic lymph node in the left supraclavicular fossa 
(Virchow's node) or left axilla (Irish's node). As the submucosal lymphatic supply of the 
stomach becomes extensively involved with tumor, other routes of lymphatic drainage may 
be recruited. Tumor spread to the lymphatics in the hepatoduodenal ligament can extend 
along the falciform ligament and result in subcutaneous periumbilical tumor deposits 
known as Sister Mary Joseph's nodes.  
Wide spread metastatic disease may occur in any organ via lymphatics, haematogenous or 
transperitoneal spread especially to liver, lungs, ovary(Krukenberg tumor) and 
peritoneum.Sclerotic bone metastatis and carcinomatous meningitis may at times occur. 
 
 Pathology and Tumor Biology  
Approximately 95% of all malignant gastric neoplasms are adenocarcinomas, and in 
general, the term gastric cancer refers to adenocarcinoma of the stomach. Other malignant 
tumors are very rare and include squamous cell carcinoma, adenoacanthoma, carcinoid 
tumors, and leiomyosarcoma. Although no normal lymphoid tissue is found in the gastric 
mucosa, the stomach is the most common site for lymphomas of the gastrointestinal tract. 
The increased awareness of association between mucosa-associated lymphoid tissue 
lymphomas and H pylori may explain, in part, the rise in incidence. The differentiation 
between adenocarcinoma and lymphoma can sometimes be difficult but is essential because 
staging, treatment, and prognosis are different for each disease.  
 
Histopathology 
Several staging schemas have been proposed based on the morphologic features of gastric 
tumors. The Borrmann classification divides gastric cancer into five types depending on 
macroscopic appearance. Type I represents polypoid or fungating cancers, type II 
encompasses ulcerating lesions surrounded by elevated borders, type III represents 
ulcerated lesions infiltrating the gastric wall, type IV are diffusely infiltrating tumors, and 
type V are unclassifiable cancers.(20)The gross morphologic appearance of gastric cancer 
and the degree of histologic differentiation are not independent prognostic variables.21,22 
Ming22`has proposed a histomorphologic staging system that divides gastric cancer into 
either a prognostically favorable expansive type or a poor-prognosis infiltrating type. Based 
on an analysis of 171 gastric cancers, the expansive-type tumors were uniformly polypoid 
or superficial on gross appearance, whereas the infiltrative tumors were almost always 
diffuse. Grossly ulcerated lesions were equally divided between the expanding or 
infiltrative forms. Broder's classification of gastric cancer grades tumors histologically 
from 1 (well differentiated) to 4 (anaplastic). Bearzi and Ranaldi23have correlated the 
degree of histologic differentiation with the gross appearance of 41 primary gastric cancers 
seen on endoscopy. Ninety percent of protruding or superficial cancers were well 
differentiated (Broder's grade 1), whereas almost one-half of all ulcerated tumors were 
poorly differentiated or diffusely infiltrating (Broder's grades 3 and 4).  
The most widely used classification of gastric cancer is by Lauren.18 It divides gastric 
cancers into either intestinal or diffuse forms. This classification scheme, based on tumor 
histology, effectively characterizes two varieties of gastric adenocarcinomas that manifest 
distinctively different pathology, epidemiology, and etiologies. The intestinal variety 
represents a differentiated cancer with a tendency to form glands. In contrast, the diffuse 
form exhibits very little cell cohesion and has a predilection for extensive submucosal 
spread and early metastases. Although the diffuse-type cancers are generally associated 
with a worse outcome than the intestinal type, this finding is not independent of tumor, 
node, metastasis (TNM) stage.The WHO classification based on histology consists of 
Papillary,Tubular,Mucinous and signet cell types. 
  
Patterns of Spread  
Carcinomas of the stomach can spread by local extension to involve adjacent structures and 
can develop lymphatic metastases, peritoneal metastases, and distant metastases. These 
extensions can occur by the local invasive properties of the tumor, lymphatic spread, or 
hematogenous dissemination. The initial growth of the tumor occurs by penetration into the 
gastric wall, extension through the wall, and involvement of an increasing percentage of the 
stomach. The two modes of local extension that can have a major therapeutic impact are 
tumor penetration through the gastric serosa, where the risk of tumor invasion of adjacent 
structures or peritoneal spread is increased, and involvement of lymphatics. Zinninger24 has 
evaluated the spread in the gastric wall and has found a wide variation in its extent. Tumor 
spread is often through the intramural lymphatics or in the subserosal layers. Local 
extension can also occur into the esophagus or the duodenum. Duodenal extension is 
principally through the muscular layer by direct infiltration and through the subserosal 
lymphatics, but is not generally of great extent. Extension into the esophagus occurs 
primarily through the submucosal lymphatics. 
  
Local extension does not occur solely by radial intramural spread but also by deep invasion 
through the wall to involve adjacent structures. Extension can occur through the gastric 
serosa to involve omentum, spleen, adrenal gland, diaphragm, liver, pancreas, or colon. 
Data from several large older series indicated that 60% to 90% of patients had primary 
tumors penetrating the serosa or invading adjacent organs and that at least 50% had 
lymphatic metastases.25,26 Of the 1577 primary gastric cancer cases admitted to Memorial 
Sloan-Kettering Cancer Center between July 1, 1985, and June 30, 1998, 60% of the 1221 
resected cases had evidence of serosal penetration, and 68% had positive nodes. Lymph 
node metastases were found in 18% of pT1 lesions after R0 resection in 941 patients. This 
rate increased significantly to 60% in pT2 lesions. The highest incidence of lymphatic 
metastasis was seen in tumors diffusely involving the entire stomach. Tumors located at the 
gastroesophageal junction also had a high incidence relative to other sites. The pattern of 
nodal metastases also varies depending on the location of the primary site with the left 
gastric artery nodes being consistently at increased risk for nodal metastases, regardless of 
tumor location. 
  
Gastric cancer recurs in multiple sites, locoregionally and systemically The literature 
reveals disagreements over failure patterns : these disagreements are likely related to the 
patient cohorts accepted for evaluation, the time at which failure was determined, and the 
method of determination of failure patterns. In two older autopsy series, the rate of 
locoregional failure [defined as tumor in perigastric tissues (e.g., in the retroperitoneal 
"gastric bed," perigastric lymph nodes, gastric remnant)] after potentially curative resection 
was 40% to 80%27,28 Many patients had multiple sites of local failure. Shiu and coworkers25 
found a 23% local recurrence rate in 169 patients treated for carcinoma of the body of the 
stomach. 
  
Gunderson and Sosin29reanalyzed the reoperation series performed by Wangensteen at the 
University of Minnesota, where patients had a second-look laparotomy after resection of 
the primary tumor. This type of analysis is valuable because it can demonstrate the early 
(and perhaps most treatable) modes of failure, rather than simply showing diffuse 
metastatic disease at autopsy. Sixty-nine percent of patients had evidence of a locoregional 
recurrence, and 42% had peritoneal seeding. Most of the local failures were located in the 
gastric bed (81%), although recurrences also occurred in the anastomosis or stump (39%) 
or in the regional lymph nodes (63%). A trial from the British Stomach Cancer Group 
found the incidence of local failure in patients treated with surgery alone to be 37 of 69 
(54%)30 A series evaluating local failure patterns reported by Landry et al.31 showed a total 
locoregional failure rate of 38%, with most of the local recurrences in the gastric bed, the 
anastomosis, or the gastric stump. The incidence of local failure increased when the 
primary disease extended through the gastric wall or when lymph nodes were involved at 
the initial surgery. Liver metastases occurred in 30% of patients and peritoneal seeding in 
23%. Extraabdominal failure was relatively rare and occurred in 13% of patients.  
Some newer series suggest a higher incidence of peritoneal seeding as a failure pattern. 
Wisbeck et al.100 evaluated autopsy and clinical records of 85 patients who died of gastric 
cancer. Sixteen patients had a resection with curative intent; 15 of these developed a 
locoregional recurrence, 8 developed peritoneal seeding, and 7 developed lung metastases. 
Of the entire cohort, 40 of 85 (47%) developed peritoneal seeding. Ajani et al.32treated 25 
patients with preoperative chemotherapy. At the time of surgery, eight had peritoneal 
carcinomatosis, and it developed subsequently in an additional five patients. Because 
imaging studies were not done routinely postoperatively, they could not accurately 
determine the risk of locoregional failure. These data suggest that increased attention to 
methods of controlling local and regional disease as well as systemic disease is needed to 
improve long-term results.  
 
Clinical Presentation and Pretreatment Evaluation  
Signs and Symptoms   
Because of the vague, nonspecific symptoms that characterize gastric cancer, most patients 
are diagnosed with advanced-stage disease. Patients may have a combination of signs and 
symptoms such as weight loss, anorexia, fatigue, or epigastric discomfort, none of which 
unequivocally indicates gastric cancer.  
Weight loss is a common symptom, and its clinical significance should not be 
underestimated. Dewys and colleagues found that, in 179 patients with advanced, 
nonmeasurable gastric cancer, more than 80% had a greater than 10% decrease in body 
weight before diagnosis. Furthermore, patients with weight loss had a significantly shorter 
survival than did those without weight loss.  
In some patients, symptoms may suggest the presence of a lesion at a specific location. A 
history of dysphagia may indicate the presence of a tumor in the cardia with extension 
through the gastroesophageal junction. Early satiety is an infrequent symptom of gastric 
cancer but is indicative of a diffusely infiltrative tumor that has resulted in loss of 
distensibility of the gastric wall. Persistent vomiting is consistent with an antral carcinoma 
obstructing the pylorus. Significant gastrointestinal bleeding is uncommon with gastric 
cancer; however, hematemesis does occur in approximately 10% to 15% of patients. 
Ascites, jaundice, or a palpable mass indicates extensive and incurable disease. Signs and 
symptoms at presentation are often related to spread of disease. Because the transverse 
colon is held in proximity to the stomach by the gastrocolic ligament, the transverse colon 
is a potential site of malignant fistulization and obstruction from a gastric primary tumor. 
Diffuse peritoneal spread of disease frequently produces other sites of intestinal 
obstruction. A large ovarian mass (Krukenberg's tumor) or a large peritoneal implant in the 
pelvis (Blumer's shelf), which can produce symptoms of rectal obstruction, may be felt on 
pelvic or rectal examination. Nodular metastases in the subcutaneous tissue around the 
umbilicus or in peripheral lymph nodes represent areas in which a tissue diagnosis can be 
established with minimal morbidity.  
 
Screening 
Mass screening programs for gastric cancer have been most successful in high-risk areas, 
especially in Japan. A variety of screening tests have been studied in Japanese patients, 
with a sensitivity and specificity of approximately 90%. Screening typically includes the 
use of double-contrast barium radiographs or upper endoscopy.  
The yield in screened populations has been substantial; in some Japanese studies, up to 
60% of patients actively participating in routine mass screening programs have the disease 
and up to 60% of newly diagnosed patients have early gastric cancer (EGC). The latter is 
clinically important because EGC has a very high cure rate with surgical treatment. 
However, the fact that gastric cancer remains the number one cause of death in Japan 
indicates the limitations of a mass screening program when the entire population at risk is 
not effectively screened. Studies have verified that a low serum pepsinogen I/II ratio can be 
used to better select patients at increased risk for atrophic gastritis and gastric cancer. 
  
Pretreatment Staging  
Tumor Markers 
The carcinoembryonic antigen (CEA) level is elevated in approximately one-third of 
patients with primary gastric cancer. The sensitivity of CEA as a marker of gastric cancer is 
low, but when the CEA level is elevated, it generally correlates with stage. Combining 
CEA with other markers, such as the sialylated Lewis antigens CA19-9 or CA50, can 
increase sensitivity, compared with CEA alone. 
  
A large study of patients with gastric cancer evaluated the prognostic significance of serum 
levels of CEA (n = 237), -fetoprotein (n = 164), human chorionic gonadotropin-  ( -
HCG; n = 165), CA19-9 (n = 64), and CA125 (n = 104), as well as tissue staining for C-erb 
B-2 (n = 160) and -HCG (n = 160). In a multivariate analysis, only a serum -HCG level 
of 4 IU/L or greater (hazard ratio, 1.7; 95% CI, 2.8 to 1.1) and a CA125 level of 350 U/mL 
or greater (hazard ratio, 2.2; 95% CI, 4.2 to 1.2) had prognostic significance. Elevated 
serum -HCG and CA125 levels in gastric cancer before chemotherapy may reflect not just 
tumor burden but also aggressive biology; however, the utility of these markers in staging 
must be compared to that of other known preoperative markers of stage, such as on T- and 
N-stage endoscopic ultrasonography (EUS). 
  
Endoscopy 
Endoscopy is generally considered to be the best method to diagnose gastric cancer. 
Endoscopy directly visualizes the gastric mucosa and allows biopsy of tissue for a 
histologic diagnosis.  
 
EUS is presently available in some centers, and, although mainly used to further stage 
previously diagnosed tumors, it may be helpful in identifying early diffuse-type gastric 
carcinoma lesions that might otherwise be overlooked. EUS has the added capability to 
evaluate the deeper layers of the gastric wall to help define the T stage of the tumor and 
provide information on the morphologic status of surrounding lymph nodes. EUS has an 
accuracy of up to 90% for T staging of gastric tumors and 75% for N staging; these rates 
are higher than those for preoperative computed tomography (CT) scans.  
 
Computed Tomography  
Once gastric cancer is suspected, CT of the abdomen and pelvis is an important part of the 
staging evaluation. Patients with Siewert type I or II tumors should also undergo a chest 
CT.  
CT is useful for noninvasive assessment of perigastric lymphadenopathy, peritoneal 
disease, and intraabdominal visceral (primary liver) metastatic disease and for estimation of 
the degree of tumor penetration through the gastric wall. With modern multiphase, 
multidetector spiral CT imaging, there is increased accuracy in the assessment of 
extragastric disease and mural penetration (particularly for T2 and greater tumors). The 
accuracy of CT assessment of tumor location and T stage can be enhanced over that of 
conventional helical CT by use of water as an oral contrast agent—so called helical hydro-
CT.  
 
Positron Emission Tomography  
Whole body 2-[18F]fluoro-2-deoxyglucose (FDG)–positron emission tomography (PET) is 
being applied increasingly in the evaluation of gastrointestinal malignancies. A relative 
paucity of data is available on the role of PET in the staging of gastric cancer. A few pilot 
studies of PET imaging for gastric cancer (all stages) and the use of PET in the detection of 
recurrent disease have been reported. The absence of meaningful data on PET for staging 
gastric cancer contrasts with esophageal cancer, for which PET has an increasingly well-
defined role in pretreatment staging.  
Important differences in tumor biology may limit the role for PET in gastric cancer. For 
example, the glucose transporter-1, an important transporter of FDG into tumor cells, is 
rarely present in common subtypes of gastric carcinoma, including signet-ring cell 
carcinoma and mucinous adenocarcinoma (2.0% and 6.3%, respectively). This may 
contribute to false-negative FDG-PET imaging. Interestingly, the presence of glucose 
transporter-1 and FDG-avid gastric cancers is associated with decreased overall survival.  
 
Laparoscopy 
Staging laparoscopy has become an accepted part of the pretreatment staging evaluation of 
patients who are believed to have localized gastric cancer after initial helical CT 
assessment. The rationale for laparoscopic staging is based on the fact that sensitivity of CT 
for detection of extragastric disease declines with the size of metastases. Indeed, current CT 
techniques cannot consistently identify low-volume macroscopic metastases that are 5 mm 
or less in size. Laparoscopy allows for direct inspection of the peritoneal and visceral 
surfaces for detection of CT-occult small-volume metastases. Staging laparoscopy also 
allows for assessment of peritoneal cytology and intraperitoneal evaluation with adjunctive 
diagnostic techniques such as laparoscopic ultrasound (LUS). Patients who are found to 
have occult metastatic disease at laparoscopy are considered incurable, and the use of 
laparoscopy allows them to avoid laparotomy. 
  
The rate of detection of CT-occult M1 disease by laparoscopy is dependent on the quality 
of CT scanning and interpretation. Studies from the 1990s (during which time there was 
inconsistent use of the more sensitive helical CT technique) demonstrated that CT-occult 
disease could be identified in 13% to 37% of patients. It is likely that the yield of 
laparoscopy may be somewhat lower than this with more widespread use of higher-quality 
helical CT preliminary staging. Nonetheless, even high-quality helical CT is insufficiently 
sensitive for detection of low-volume extragastric disease, and, thus, laparoscopy, CT, and 
EUS are complementary staging studies. 
  
A number of unresolved issues remain regarding the timing and extent of laparoscopy that 
should be performed for optimal staging. Laparoscopy can be performed as a separate 
staging procedure before definitive treatment planning or immediately before planned 
laparotomy for gastrectomy. When performed as a separate procedure, laparoscopy has the 
disadvantage of the additional risks and expense of a second general anesthetic. However, 
separate procedure laparoscopy allows the additional staging information acquired at 
laparoscopy to be reviewed and discussed with the patient and multidisciplinary treatment 
group before definitive treatment planning. This is important in some settings because 
laparoscopic staging findings that may alter therapeutic options and prognosis (e.g., 
peritoneal cytology) are not always available on a real-time basis during laparoscopy. 
Consequently, the timing of laparoscopy varies in different centers depending on factors 
such as the availability of intraoperative cytology assessment and the use of preoperative 
treatment approaches.  
The extent of laparoscopic evaluation is another unresolved staging issue. LUS and 
"extended laparoscopy" are techniques that may increase the diagnostic yield of 
laparoscopy. LUS involves examination of the stomach, perigastric region, and peritoneal 
cavity using a laparoscopic ultrasound probe, whereas extended laparoscopy involves a 
more detailed laparoscopic examination of the perigastric region that includes laparoscopic 
examination of the lesser sac and retrogastric space (i.e., more than simple inspection of the 
stomach and peritoneal cavity). Preliminary results reveal conflicting data on the added 
benefit of LUS and extended laparoscopy. Further studies are required to evaluate the cost-
benefit relationship of these advanced laparoscopic techniques to better define whether 
LUS and extended laparoscopy have a routine or selective role in patients undergoing 
conventional laparoscopic staging.  
Staging, Classification, and Prognosis  
The uniform and accurate staging of gastric cancer is essential to predict prognosis and 
assess outcome meaningfully. For patients with surgically treated gastric adenocarcinoma, 
pathologic staging [American Joint Committee on Cancer/International Union Against 
Cancer (AJCC/UICC), or Japanese system] and classification of the completeness of 
resection (R) should be done. In addition, although not formal components of AJCC stage 
grouping, the histopathologic grade and type and, when available, the peritoneal lavage 
cytology status should be recorded. The latter is important because the presence of free 
peritoneal cancer cells has been shown by a number of investigators to carry a prognosis 
comparable to that of visceral metastatic disease. 
 
American Joint Committee on Cancer/International Union Against 
Cancer Tumor, Node, Metastasis Staging  
The AJCC/UICC TNM staging system for gastric cancer is outlined in table.33 
In the AJCC/UICC staging system, tumor (T) stage is determined by depth of tumor 
invasion into the gastric wall and extension into adjacent structures.  
Nodal stage (N) is based on the number of involved lymph nodes—a criterion that may 
predict outcome more accurately than the location of involved lymph nodes.34,35Tumors 
with 1 to 6 involved nodes are classified as pN1, 7 to 15 involved nodes as pN2, and more 
than 15 involved nodes as pN3. The use of numeric thresholds for nodal classification has 
become increasingly more accepted, although the extent of lymphadenectomy and rigor of 
pathologic assessment may affect results.36The threshold approach is based on observations 
that survival decreases as the number of metastatic lymph nodes increase35,37and that there 
are decreases in survival at four or more involved38,39and again at seven or more involved 
lymph nodes.34,40Given the reliance on numeric thresholds for nodal staging, it is extremely 
important that surgeons and pathologists work together to ensure that adequate numbers of 
lymph nodes are retrieved and examined. Indeed, reports document poor compliance with 
AJCC staging primarily because the numbers of lymph nodes removed or examined, or 
both, were insufficient (15 or less).41,42 
 
Ratio-based lymph node classification is an alternative to the threshold-based system 
currently used for AJCC/UICC staging. This alternative approach may minimize the 
confounding effects of regional variations in the extent of lymphadenectomy and in 
pathologic evaluation of the lymphadenectomy specimen on lymph node staging and 
thereby reduce the impact of stage migration. Several reports have evaluated ratio-based 
lymph node staging.34,36,43,44Bando et al.43 evaluated the ratio of metastatic to uninvolved 
lymph nodes (RML) in a group of 650 patients who underwent R0 gastrectomy with D2 
lymph node dissection. The anatomic location, number of positive lymph nodes (as used in 
the current AJCC/UICC system), and RML were analyzed for staging accuracy and 
relationship to patient survival. RML was found to be an independent prognostic factor for 
survival and reduced the frequency of stage migration from 15% (when numeric thresholds 
were used for staging) to 7%. These findings were confirmed in a separate analysis of 1019 
patients treated by R0 gastrectomy at Kansai Medical University in Japan.44 On the basis of 
these reports, ratio-based lymph node staging should be considered for future versions of 
gastric cancer staging systems.  
 
 
Japanese Staging System  
The most recent Japanese Classification for Gastric Carcinoma was published in 1998 as 
outlined in table 3.45 The Japanese classification and staging system are more detailed than 
the AJCC/UICC staging system and place more emphasis on the distinction between 
clinical, surgical, pathologic, and "final" staging (prefixes "c," "s," "p," and "f," 
respectively). For example, a surgically treated and staged patient with locally advanced, 
nonmetastatic gastric cancer might be staged as pT3, pN2, sH0, sM0, f stage IIIB (where 
H0 denotes no hepatic metastases and the "f" prefix denotes final clinicopathologic stage). 
The Japanese classification system also includes a classification system for EGC. 
 
Similar to the AJCC/UICC staging system, primary tumor (T) stage in the Japanese system 
is based on the depth of invasion and extension to adjacent structures. However, the 
assignment of lymph node (N) stage involves much more rigorous pathologic assessment 
than is required for AJCC/UICC staging. The Japanese system extensively classifies 18 
lymph node regions into four N categories depending on their relationship to the primary 
tumor and anatomic location.45  Most perigastric lymph nodes (nodal stations 1 to 6) are 
considered group 1. Lymph nodes situated along the proximal left gastric artery (station 7), 
common hepatic artery (8), celiac axis (9), splenic artery (11), and proper hepatic artery 
(12) are defined as group 2. Paraaortic lymph nodes (16) are defined as group 3. The 
presence or absence of pathologically positive lymph nodes in each lymph node group is 
reflected in the assigned N stage. 
  
The Japanese staging system also includes elements not included in the AJCC/UICC 
system . These are macroscopic description of the tumor (EGC subtype or Borrmann type 
for more advanced tumors), extent of peritoneal metastases (classified as P0-1), extent of 
hepatic metastases (H0-1), and peritoneal cytology findings (CY0-1).45  
A comparison of the Japanese and AJCC/UICC staging systems suggested that the 
AJCC/UICC system more accurately estimates prognosis.36 Nonetheless, the 
comprehensive "c," "s," "p," and "f" prefix system used in the Japanese system provides a 
succinct and accurate summary of an individual patient's extent of disease.  
 
 
 
Classification of Esophagogastric Junction Cancers  
Siewert and Stein46 have developed a classification system for adenocarcinoma of the 
esophagogastric junction. Now commonly referred to as the Siewert classification, this 
system recognizes three distinct clinical entities that arise within 5 cm of the junction of the 
tubular esophagus and the stomach as shown in figure.  
 
Type 1—adenocarcinoma of the distal esophagus, which usually arises from an area with 
specialized intestinal metaplasia of the esophagus (i.e., Barrett's esophagus) and may 
infiltrate the esophagogastric junction from above  
Type II—adenocarcinoma of the cardia, which arises from the epithelium of the cardia or 
from short segments with intestinal metaplasia at the esophagogastric junction  
Type III—adenocarcinoma of the subcardial stomach, which may infiltrate the 
esophagogastric junction or distal esophagus from below  
The assignment of tumors to one of these subtypes is based on morphology and the 
anatomic location of the epicenter of the tumor. Classification can be performed based on 
the results of contrast radiography, endoscopy, CT, and operative findings. The Siewert 
classification system has been endorsed by the International Society for Diseases of the 
Esophagus and the International Gastric Cancer Association.  
The Siewert classification has important therapeutic implications.47 The lymphatic drainage 
routes differ for type 1 versus type II and III lesions. As shown on lymphographic studies, 
the lymphatic pathways from the lower esophagus pass cephalad (into the mediastinum) 
and caudad (toward the celiac axis). In contrast, the lymphatic drainage from the cardia and 
subcardial regions is toward the celiac axis, splenic hilus, and paraaortic nodes. Thus, the 
Siewert classification provides a practical means for choosing among surgical options. For 
type I tumors, esophagectomy is required, whereas type II and III tumors can be treated by 
transabdominal extended gastrectomy (resection of the stomach and distal intraabdominal 
esophagus).47  
 
R Classification 
The R classification system indicates the amount of residual disease left after tumor 
resection.48 R0 indicates no gross or microscopic residual disease; R1 indicates microscopic 
residual disease, and R2 signifies gross residual disease. The R classification has 
implications for individual patient care and clinical research. Surgeons should wait for the 
final pathology results before completing their operative summaries so that patient records 
include the R classification for the gastrectomy. Results of clinical trials that include 
surgery should include information on R status.  
Readers should be aware of the dual use of the "R" terminology in the gastric cancer 
literature. Before 1995, the Japanese staging and treatment descriptive vernacular included 
an "R level," which described the extent of lymphadenectomy according to the highest 
echelon of lymph nodes included in the lymphadenectomy. The latter is now classified by 
"D" (for dissection) level. Care should be exercised in current use of the R classification, 
restricting such use to describe the completeness of resection (R0-2).  
 
Predicting Individual Patient Prognosis  
Kattan et al.49  have developed a nomogram for estimating 5-year disease-specific survival 
using established prognostic factors derived from a population of 1039 gastric cancer 
patients treated by R0 surgical resection at a single institution. Clinicopathologic factors 
incorporated in the nomogram include patient age and gender, primary tumor site, Lauren 
classification, tumor size and depth, and the numbers of positive and negative lymph nodes. 
For patients with surgically treated gastric carcinoma, the nomogram estimates the 
probability of individual (i.e., personal) survival unencumbered by specific knowledge of 
prognostic factors, relative risk, or the risk group in which he/she may belong. This tool 
may be useful for individual patient counseling, follow-up scheduling, and clinical trial 
eligibility assessment. 
 
Stage II and Stage III Disease  
Surgery 
Surgical resection is the cornerstone of treatment for patients with localized gastric cancer; 
indeed, surgical resection can be curative in most patients with EGC. However, for stage II 
and III disease, surgery is necessary but often not sufficient for cure. The general 
therapeutic goal is to achieve a micro- and macroscopically complete resection (R0). 
Specific surgical issues including the extent of gastrectomy, extent of lymph node 
dissection, and role of partial pancreatectomy and splenectomy. 
 
Extent of Resection for Mid and Distal Gastric Cancers  
The extent of gastrectomy required for satisfactory primary tumor treatment depends 
mostly on the gross and microscopic status of surgical margins. For most clinical situations, 
a 5-cm grossly negative margin around the tumor and microscopically negative surgical 
margins (R0) are the treatment goals. When gastrectomy is performed with curative intent, 
frozen-section assessment of proximal and distal resection margins should be used 
intraoperatively to improve the likelihood that an R0 resection has been performed.  
 
Three relatively small, prospective randomized controlled trials (RCTs) have compared 
total gastrectomy to partial (subtotal) gastrectomy for distal gastric cancer.50-52 Overall 
morbidity, mortality, and oncologic outcome were comparable in each of these RCTs. As a 
result, when the general oncologic goal of an R0 resection can be achieved by a gastric-
preserving approach, partial gastrectomy is preferred over total gastrectomy. This is 
particularly relevant for distal gastric cancers, for which a gastric-preserving R0 approach 
may minimize the risks of specific sequelae of total gastrectomy, such as early satiety, 
weight loss, and the need for vitamin B12 supplementation. 
  
Extent of Resection for Proximal Gastric Cancer  
Many choices are available for surgical management of adenocarcinomas arising at the 
esophagogastric junction or in the proximal stomach (Siewert types II and III). Many 
abdominal surgeons have advocated transabdominal approaches with resection of the lower 
esophagus and proximal stomach or total gastrectomy. Surgeons trained in thoracic surgery 
have frequently advocated a combined abdominal and thoracic procedure (often termed 
esophagogastrectomy), with an intrathoracic or cervical anastomosis between the proximal 
esophagus and the distal stomach, or a procedure termed transhiatal (or blunt) 
esophagectomy (THE), which involves resection of the esophagus and gastroesophageal 
junction, with mediastinal dissection performed in a blunt fashion through the esophageal 
hiatus of the diaphragm. When THE is performed for adenocarcinoma of the 
esophagogastric junction, gastrointestinal continuity is restored by low cervical 
anastomosis of the stomach (usually advanced through the esophageal bed in the 
mediastinum) to the low cervical esophagus. Selection among the options has been 
dependent primarily on individual surgeon training and experience.  
 
The optimal surgical procedure for patients with localized tumors of the esophagogastric 
junction and proximal stomach is a matter of considerable debate. A Dutch RCT compared 
transthoracic esophagogastrectomy (TTEG, with abdominal and thoracic incisions) to THE 
in 220 patients with adenocarcinoma of the esophagus and esophagogastric junction.53 
Although this trial was designed for patients with esophageal cancer, 40 (18%) of the 
patients had adenocarcinomas of the esophagogastric junction (Siewert type II), and the 
operations evaluated are among those considered for patients with Siewert type II or III 
cancers. Perioperative morbidity was higher after THE, but there was no significant 
difference in in-hospital mortality compared to TTEG. Although median overall, disease-
free, and quality-adjusted survival did not differ significantly between the groups, there 
was a trend toward improved overall survival at 5 years with TTEG. These results are 
believed to be equivocal,54 and there is currently no consensus on the optimal surgical 
approach for patients with Siewert type II tumors. Until longer follow-up of the Dutch trial 
is available or additional RCTs are performed, or both, the surgical approach to these 
patients will continue to be individualized—determined by a constellation of factors, 
including surgeon factors (training and experience), patient factors (age, comorbidity, and 
performance status), and tumor factors (pretreatment T and N stage). 
  
Extent of Lymphadenectomy  
The dialogue surrounding lymphadenectomy involves at least two important issues: (1) 
staging—removal and histopathologic analysis of an "adequate" number of lymph nodes, 
and (2) therapy—are some forms of lymphadenectomy therapeutic for patients with gastric 
cancer?55–57 
  
Single-institution reports suggest that the number of pathologically positive lymph nodes is 
of prognostic significance40,58 and that removal and pathologic analysis of at least 15 lymph 
nodes are required for adequate pathologic staging.35 Indeed, the current AJCC staging 
system (6th edition) accounts for these issues and therefore requires analysis of 16 or more 
lymph nodes to assign a pathologic N stage.59 The multidisciplinary clinical correlates of 
this are obvious: (1) Surgeons must perform an adequate lymphadenectomy, and (2) 
pathologists must retrieve and examine at least 16 lymph nodes to provide optimal 
pathologic staging.  
The possible therapeutic benefit of extended lymph node dissection has been the focus of 
four RCTs,.These trials were performed because retrospective63,64 and prospective 
nonrandomized65 evidence suggested that extended lymph node dissection may be 
associated with improved long-term survival. The RCTs tested the hypothesis that removal 
of additional pathologically positive lymph nodes (not generally removed as part of a 
standard lymph node dissection) improves survival. The larger RCTs attempted to follow 
what are referred to as the Japanese rules for lymph node classification and dissection66 that 
govern the extent of nodal dissection required based on anatomic location of the primary 
tumor. Using these Japanese definitions, the RCTs compared limited lymphadenectomy of 
the perigastric lymph nodes (D1 dissection) to en bloc removal of second-echelon lymph 
nodes (D2 dissection). At least two of the trials50,60 are underpowered for their primary end 
point—overall survival. The most recent trials from the Medical Research Council (MRC) 
of the United Kingdom61 and the Dutch Gastric Cancer Group62 have received the most 
attention and discussion.  
 
The MRC trial registered 737 patients with gastric adenocarcinoma; 337 (46%) patients 
were ineligible by staging laparotomy because of advanced disease, and 400 (54%) were 
randomized at the time of laparotomy to undergo D1 or D2 lymph node dissections. 
Postoperative morbidity was significantly greater (46% vs. 28%; P <.001), and in-hospital 
mortality was significantly higher in the D2 group than in the D1 group (13% vs. 6%, P 
<.04; 95% CI for D2, 4% to 11%).67 The excess morbidity and mortality seen in the D2 
group was thought to be related to the routine use of distal (left) pancreatectomy and 
splenectomy. Partial pancreatectomy and splenectomy were performed to maximize 
clearance of lymph nodes at the splenic hilum—primarily for patients with proximal 
tumors; however, many surgeons now believe that adequate lymph node dissection can be 
performed with pancreas- and spleen-preserving techniques. Long-term follow-up analysis 
of patients in the MRC trial demonstrated comparable 5-year overall survival rates of 35% 
and 33% in the D1 and D2 dissection groups, respectively (difference, –2%; 95% CI, –12% 
to 8%). Survival based on death from gastric cancer as the event was also similar in the D1 
and D2 groups (hazard ratio = 1.05; 95% CI, 0.79 to 1.39), as was recurrence-free survival 
(hazard ratio = 1.03; 95% CI, 0.82 to 1.29).61 The authors concluded that classic Japanese-
style D2 lymphadenectomy (with partial pancreatectomy and splenectomy) offered no 
survival advantage over D1 lymphadenectomy.  
 
The Dutch Gastric Cancer Group conducted a larger RCT with optimal surgical quality 
control comparing D1 to D2 lymph node dissection for patients with gastric 
adenocarcinoma; 996 patients were registered, and 711 (71%) were randomized to D1 
dissection (n = 380) or D2 dissection (n = 331). To maximize surgical quality control, all 
operations were monitored.68 Initially, this oversight was done by a Japanese surgeon who 
trained a group of Dutch surgeons; they, in turn, acted as supervisors during surgery at 80 
participating centers. Notwithstanding the extraordinary efforts to ensure quality control of 
the two types of lymph node dissection, noncompliance (not removing all lymph node 
stations) and contamination (removing more than was indicated) occurred, blurring the 
distinction between the two operations and confounding the interpretation of the oncologic 
end points.69 The postoperative morbidity was higher in the D2 group (43% vs. 25%, P 
<.001), and the mortality was also significantly higher in the D2 group (10% vs. 4%, P = 
.004). Patients treated with D2 dissection also required a longer hospitalization.70 As in the 
MRC trial, partial pancreatectomy and splenectomy were performed en passant in the D2 
group. Five-year survival rates were similar in the two groups: 45% for the D1 group and 
47% for the D2 group (95% CI for the difference, –9.6% to 5.6%). The subset of patients 
who had R0 resections, excluding those who died postoperatively, had cumulative risks of 
relapse at 5 years of 43% with D1 dissection and 37% with D2 dissection (95% CI for the 
difference, –2.4% to 14.4%). The Dutch investigators concluded that there was no role for 
the routine use of D2 lymph node dissection in patients with gastric cancer.  
 Interpretation of the existing level 1 evidence is encumbered by a number of issues.66,67 The 
primary concerns relate to whether (1) the increased operative mortality associated with 
protocol-mandated partial pancreatectomy and splenectomy for patients with proximal 
tumors undergoing D2 dissection prevented identification of a potential therapeutic impact 
of extended lymph node dissection, and (2) the phenomena of noncompliance and 
contamination led to homogenization of the operative procedures to such an extent that the 
fundamental hypothesis was not tested. Owing to these interpretation issues, the question of 
a possible therapeutic benefit of D2 dissection remains unsettled. 
  
Many Japanese gastric surgeons have considered the caveats associated with the MRC and 
Dutch trials and believe that, notwithstanding inherent patient selection and stage migration 
biases,56,69 the existing retrospective data provide sufficient proof of a clinical benefit of D2 
dissection. On this basis, D2 dissection has been adopted as the standard of care for patients 
with localized, higher-risk gastric cancer in many centers in Japan and some specialized 
centers in the West.61 In Japan, the Japan Clinical Oncology Group (JCOG) has 
investigated an even more aggressive surgical approach in an RCT evaluating paraaortic 
lymphadenectomy in the management of completely resected (R0) T2 to T4 gastric cancer. 
Between July 1995 and April 2001, 523 patients from 25 institutions were registered. 
Patients were randomized intraoperatively to undergo D2 lymphadenectomy alone or D2 
lymphadenectomy plus paraaortic lymph node dissection (D3). The primary end point is 
overall survival; only preliminary morbidity and mortality results have been reported.100 
The patients treated with D3 dissection had longer operation times, greater blood loss, and 
a higher frequency of blood transfusion than did the group that underwent D2 dissection. 
However, the groups had no significant differences in postoperative complications, and 
only two patients (0.8%, one in each group) died of postoperative complications. These 
findings demonstrate that the addition of paraaortic lymph node dissection to D2 dissection 
in Japanese patients does not significantly increase the rate of postoperative morbidity or 
mortality. 
  
Partial Pancreatectomy and Splenectomy: Resect or Preserve?  
Partial (left, distal) pancreatectomy and splenectomy have been performed as part of D2 
lymph node dissection to remove the lymph nodes along the splenic artery (station 11) and 
at the splenic hilum (station 12)—primarily for patients with tumors located in the proximal 
and mid stomach. Indeed, partial pancreatectomy and splenectomy were required for 
patients with proximal tumors in the D2 arm of the Dutch and MRC RCTs but were 
required only for direct tumor extension in the D1 arm. Splenectomy is associated with an 
increased risk for surgical complications and postoperative death. In addition, a 
multivariate analysis suggested that splenectomy is associated with inferior long-term 
survival. The frequent performance of splenectomy (e.g., 30% of patients in the D2 arm vs. 
3% in the D1 arms of the Dutch trial) with its associated adverse effects on short- and long-
term mortality confounds the interpretation of the Dutch and MRC RCTs. Thus, the 
hypothesis that spleen- and pancreas-preserving D2 lymph node dissection improves 
survival remains unproven.  
 
Increasingly, experienced gastric surgeons have acknowledged the adverse effects of 
splenectomy. The evolving consensus is that splenectomy should be performed only in 
cases with intraoperative evidence of direct tumor extension into the spleen or when the 
primary tumor is located in the proximal stomach along the greater curvature. Partial 
pancreatectomy should be performed only in cases of direct tumor extension to the 
pancreas.  
 
Reports have described pancreas- and spleen-preserving forms of D2 dissection.72–74 This 
organ-preserving modification of classic D2 dissection allows for dissection of some 
station 11 and 12 lymph nodes without the potential adverse effects of pancreatectomy or 
splenectomy, or both. In a small single-institution RCT reported from Chile, Csendes et 
al.75 randomized 187 patients with localized proximal gastric adenocarcinoma to treatment 
by total gastrectomy with D2 lymph node dissection plus splenectomy or total gastrectomy 
with D2 lymphadenectomy alone. Operative mortality was similar in the two groups 
(splenectomy group, 3%; control group, 4%). However, septic complication rates were 
higher in the splenectomy arm than in the control arm (P <.04). No difference was seen in 
5-year overall survival rates, although it is not clear that the trial was designed with 
survival as the primary end point.  
 
The JCOG is conducting a multiinstitutional RCT (JCOG 0110-MF) comparing D2 
dissection with and without splenectomy for patients with proximal gastric cancer.76 The 
hypothesis to be tested is that the 5-year overall survival of patients treated by D2 
dissection without splenectomy is 5% less than that of patients treated by D2 dissection 
with splenectomy. With a planned accrual of 500 patients, this design will provide a 70% 
power to reject the null hypothesis when 5-year overall survival is 3% greater after splenic 
preservation compared with splenectomy.76 The results of this trial will elucidate the short- 
and long-term effects of splenectomy for patients with proximal gastric cancers. 
  
Individualized Assessments of Lymph Node Involvement  
Attention has focused on methods of individual assessment of risk of lymphatic spread. 
These techniques offer the possibility of tailoring surgical therapy for an individual patient 
based on clinicopathologic risk assessment of the primary tumor or pre- or intraoperative 
identification of SLNs or primary draining lymph nodes, or both. In the future, it is hoped 
that molecular determinants of lymph node metastasis will supplant these approaches. At 
present, at least three approaches to individual nodal risk assessment have been evaluated: 
computer modeling, preoperative endoscopic injection, and SLN biopsy.  
 
Preoperative Computer Modeling of Individual Patient Nodal Involvement  
Maruyama and colleagues have developed a computer program to estimate the probability 
of spread to specific nodal regions for an individual patient using his or her pretreatment 
clinicopathologic data. As initially developed, the program incorporated data on tumor size, 
depth of infiltration, location, grade, type, and macroscopic appearance of primary tumors 
from 2000 patients with surgically resected gastric cancers treated at the National Cancer 
Center of Tokyo.77 The data set used for matching individual patient data is continuously 
updated and now includes more than 8000 patients. The Maruyama computer model has 
been validated in non-Japanese patients in studies done in Germany78 and Italy.79 In the 
United States, Hundahl et al.80 retrospectively applied this computer model to evaluate the 
surgical treatment of patients entered into the Intergroup trial of adjuvant fluorouracil (FU)-
based chemoradiation. The Maruyama program was used to estimate the likelihood of 
disease in undissected regional node stations, defining the sum of these estimates as the 
Maruyama index of unresected disease. Of the participating patients, 54% underwent D0 
lymphadenectomy. The median index was 70 (range, 0 to 429). In contrast to D level, the 
Maruyama index proved to be an independent prognostic factor of survival, even with 
adjustment for the potentially linked variables of T stage and number of positive nodes.  
 
Preoperative Endoscopic Peritumoral Injection  
The hypothesis that peritumoral injection of compounds designed to optimize lymph node 
dissection improves lymph node clearance was addressed in a small RCT evaluating 
preoperative endoscopic vital staining with CH40 before D2 dissection. The frequency of 
positive lymph nodes in patients injected with CH40 before D2 dissection was greater than 
that observed in patients treated by D2 dissection alone. This approach optimized the yield 
of lymph node dissection, presumably by directing surgeons to include specific lymph 
nodes in the dissection that would have otherwise been left in situ or by directing 
pathologists to examine specific areas of the lymphadenectomy specimens, or both. Further 
prospective studies of this approach are required to confirm the feasibility of this technique 
and assess its impact on intraoperative decision making regarding the extent of 
lymphadenectomy.  
 
 
 Sentinel Lymph Node Biopsy  
The goal of SLN biopsy is to identify the node or nodes believed to be the first peritumoral 
lymph nodes in the orderly spread of gastric adenocarcinoma from the primary site to the 
regional lymph nodes. Sampling of this lymph node may allow for prediction of the nodal 
status of the entire lymph node basin—possibly obviating node dissection and its attendant 
morbidity in patients found to have a negative SLN. Pilot studies have evaluated the 
feasibility, sensitivity, and specificity of SLN biopsy for patients with gastric cancer. These 
pilot studies demonstrated that SLN identification is feasible in approximately 95% of 
patients. However, most patients with gastric cancer have multiple "sentinel" nodes, with 
mean numbers of SLNs per patient ranging from 2.6 to 6.3. It is likely that the numbers of 
identified SLNs depend on a number of factors, including anatomic location of the primary 
tumor, pathologic stage, and the node identification technique used. Most pilot studies of 
SLN biopsy have involved subsequent D2 lymph node dissection, thereby allowing 
assessment of the false-negative rate of SLN biopsy. The aggregate experience to date 
suggests that, among patients with pathologically involved lymph nodes, SLN results in 
false-negative assessment of pathologic nodal status in 11% to 60% of patients. Thus, the 
preliminary data available suggest that SLN biopsy cannot reliably replace lymph node 
dissection as a means of accurately staging regional nodal basins. Until further data are 
available, SLN biopsy should remain an investigational approach. 
 
 
 
Volume Relationships for Gastrectomy  
Studies have established a clear relationship between institutional gastrectomy volume and 
perioperative mortality. The analysis of a national database by Birkmeyer et al.81 of 31,854 
patients who underwent gastrectomy between 1994 and 1999 demonstrated an inverse 
relationship between institutional gastrectomy volume and operative mortality. The OR for 
gastrectomy-related death was lowest among patients treated at the hospitals in the highest 
gastrectomy volume quintile (OR, 0.72; 95% CI, 0.63 to 0.83). A separate analysis 
evaluating surrogate end points for morbidity demonstrated that gastrectomy at high-
volume centers was associated with the shortest duration of hospital stay and the lowest 
readmission rates.82  
Similar findings were noted by Hannan et al.83 in an analysis of the New York State 
Department of Health's administrative database. Their analysis of 3711 patients who 
underwent gastrectomy between 1994 and 1997 included adjustments for covariates such as 
age, demographic variables, organ metastasis, socioeconomic status, and comorbidities. 
Patients who had gastrectomy at hospitals in the highest-volume quartile had an absolute 
risk-adjusted mortality rate that was 7.1% lower (P <.0001) than those treated at hospitals 
in the lowest-volume quartile even though the overall mortality for gastrectomy was only 
6.2%. These studies demonstrate that the risk-adjusted mortality for gastectomy is 
significantly lower when gastrectomy is performed by high-volume providers.  
It is likely that the variations in gastrectomy-related mortality relate in part to surgeon 
training and experience with the procedure. Data on gastrectomy volume obtained from 
general surgeons undergoing recertification after a minimum of 7 years in practice 
demonstrate that the mean number of gastric resections performed by recertifying general 
surgeons in the United States is only 1.4 per year. Thus, given the data supporting a 
relationship between hospital and provider volumes and the morbidity and mortality of 
gastric resection, there are reasons to consider regionalization of the surgical treatment of 
gastric cancers.  
 
Outcome in Japan versus Western Countries  
Stage-stratified survival rates for gastric adenocarcinoma are higher in Japan than in most 
Western countries. The reasons for this are complex, are incompletely understood.  
Important differences in the epidemiology of gastric cancer may contribute to observed 
differences in outcome in Japan versus Western countries. First, the better-prognosis 
intestinal-type (Lauren classification18) tumors are seen more commonly in Japan, whereas 
the diffuse-type cancers that are associated with a poorer prognosis are more frequent in 
Western series. These regional differences in the frequencies of intestinal and diffuse 
cancers are believed to be related to the higher incidence of H pylori infection and atrophic 
gastritis in Japanese populations. Second, poorer-prognosis proximal gastric cancers are 
less frequent in Japanese than in Western populations.84,85 Indeed, the increase in proximal 
gastric cancers observed in the West10 has not been observed in Japanese populations.86 
These important differences in tumor location and Lauren subtype may contribute to 
observed differences in stage-specific outcome between Japan and Western countries.  
Regional differences in the diagnostic criteria for EGC also may contribute to regional 
differences in observed outcome. In Japan, gastric carcinoma is diagnosed based on its 
structural and cytologic features without consideration of invasion of the lamina propria. In 
contrast, Western pathologists consider invasion of the lamina propria to be an essential 
element of the diagnosis of carcinoma.87,88 As a consequence, unequivocally neoplastic 
noninvasive lesions are classified as carcinoma in Japan but as dysplasia by Western 
pathologists.87 To overcome these differences, the Padvova,89 Vienna,90 and revised 
Vienna91 classifications have been proposed. However, until there is worldwide consensus 
and implementation of uniform diagnostic criteria for EGC, comparative assessments of the 
outcome of patients with EGC treated in Japan and Western countries should acknowledge 
the selection bias associated with different diagnostic criteria.  
Stage migration is a well-documented factor contributing to the stage-specific differences 
in outcome between Japanese and Western patients.56 Stage migration arises because there 
is widespread use of extensive D2 or D3 lymphadenectomy combined with rigorous 
pathologic assessment of the lymphadenectomy specimen in Japan. In contrast, these 
techniques are infrequently used in Western countries. More accurate stage assignment of 
Japanese patients leads to secondary stage migration—improvement in stage-specific 
survival without improvement in overall survival. The frequency and impact of stage 
migration were quantified by the Dutch Gastric Cancer Group in their RCT comparing D1 
and D2 lymph node dissection.62,92 Stage migration occurred in 30% of patients in the D2 
group, and the stage-specific decreases in survival rates attributable to stage migration were 
3% for AJCC/UICC stage I disease, 8% for stage II, 6% for stage III, and 12% for stage 
IIIB, with the more accurately staged D2 group having higher survival rates.92 
In addition to regional differences in epidemiology, diagnostic criteria for early-stage 
cancers, and stage migration, other factors may contribute to the observed differences in 
stage-stratified survival. Such factors may include genetic, environmental, and biologic 
differences between Japanese and Western patients and tumors. These factors have been 
less well studied but were addressed in a comprehensive review by Davis and Sano.93 
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MATERIALS AND METHODS 
 
 
This study was conducted in Thanjavur medical college and hospital from July 2005 to 
August 2007.Out of the 398 patients diagnosed as carcinoma of stomach in the study period 
only those undergoing curative resection was taken into study based on  
 
1)Clinical examination. 
2)Investigations performed 
3)Surgery performed and  
4)Detail study of histopathology of specimen. 
 
All Patients were clinically evaluated and those with clinically evidence of metastasis were 
excluded 
Clinical evidence of metastasis: 
Supraclavicular (Virchow) Lymph node 
Left axillary (Irish) Lymph node 
Umbilical Metastasis (Sister Mary Joseph nodule) 
Malignant ascites 
Liver secondary (Nodules) and Jaundice 
Pelvic deposits 
Bone metastasis 
 
All patients who where having metastasis with investigative modality like Ultrasonagram 
and Computed tomogram of abdomen were excluded from the study. 
Ultrasound features of metastasis like liver secondaries, ascites and pelvic deposits were 
recorded. 
High resolution Computed tomogram in not available in our centre, but details of 
perigastric lymphadenopathy, peritoneal disease and intraabdominal visceral (primary 
liver) metastatic disease and for estimation of adjacent organ infiltration was assessed to 
some extent with the available facility in all patients planned for surgery. Those with OGJ 
tumor underwent CT of Chest. 
Those with suspected bone metastasis underwent skeletal survey and all patients underwent 
chest radiography. 
Endoscopy was performed in nearly all patients except those with extensive metastasis and 
poor general condition. 
All patients planned for surgery had endoscopy assessment of site, size of tumor and biopsy 
for conformation and degree of differentiation.Endoscopic ultrasonagram is not available in 
our centre. 
Tumor markers and PET scan was not done in any patient in our study. 
All patients were staged pre operatively with the above methods. 
Out of 398 patients 164 had extensive disease and were excluded and referred for best 
supportive care or palliative chemotherapy. Out of 164 patients 38 underwent Palliative 
chemotherapy and 126 patients were given supportive care. The mortality was very high in 
the patients and the longest survival being 7 months. 
 
Other 234 patients selected for various surgeries were analysed 
Curative gastrectomy 
Palliative gastrectomy 
Palliative Bypass procedures  
Feeding procedures 
In those patients who were planned for curative surgery with intraoperative findings of 
inoperability and irresectability were excluded. 
Diagnostic laparoscopy was used in selected cases before performing laparotomy.Although 
extended Laparoscopy was not performed in any patient. In patients with CT occult disease 
peritoneal lavage cytology and peritoneal biopsy was done. All 11 patients who underwent 
Laparoscopy were inoperable. 
Inoperable findings like: 
Ascites 
Liver metastasis 
Peritoneal deposits 
Pelvic deposits 
Irresectable findings like: 
Involvement and infiltration into adjacent organs like liver,pancreas,transverse colon. 
Fixity to surrounding structures 
Vascular invasion 
 
Those patients who present with macroscopic remnant tissue after resection were also 
excluded from the study. (R2) and considered as palliative resection. 
Those patients with positive resected margins (R1) were also excluded, as considered 
palliative resection. 
But patients with serosal involvement without involvement or infiltration into adjacent 
organs or structures were considered potentially curable and involved in the study. 
 
Most of patients who fulfil the criteria fall into stage II and III. 
Total no patients: 398 
Total planned some form of surgery: 234 
Total underwent curative surgery: 95 
Inoperable after planning: 139 
Palliative resection: 22 
Irresectable: 117  
Bypass procedure: 91 
Feeding procedure: 15 
Diagnostic laparoscopy and Closure: 11 
 
So 95 patients were taken into study and various factors analysed 
1) Age 
2) Sex 
3) Type of surgery performed 
              Extent of resection 
      Proximal and distal margin given 
      Resection of spleen and pancreas 
      Extent of lymph node dissection 
      Removal of pancreatic capsule 
      Involvement or infiltration into adjacent structures 
4) Site of involvement 
5) Type of tumor 
  Broader: Well, moderate or poor differentiation. 
  WHO: Papillary, Tubular, Mucinous or signet ring. 
  Lauren’s: Intestinal, Diffuse or Mixed. 
6) Size of tumor 
7) Depth of invasion 
8) Total Lymph nodes Positive 
9) Total Lymph node negative  
10) Resected margins. 
 
Based on these factors the disease specific survival was plotted using nomogram designed 
by Kattan et al. The DSS was plotted and analysed in all these patients and compared with 
other studies. This tool was used for individual patient counselling, follow up scheduling 
and adjuvant therapy. 
 
The average lymph node analysed in the study was compared with other studies. 
The extent of resection and Lymphadenectomy and their relation with survival and 
mortality were also compared with other studies. 
Surgical complication were also analysed and treated accordingly. 
Mortality and morbidity were also studied 
Most of the patients were followed up as per schedule with clinical examination, 
Endoscopy, ultrasonogram and CT. 
Those who developed recurrence were confirmed and further adjuvant therapy given. 
Patients in the study undergoing adjuvant therapy were also analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION AND DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 
 
 
In Thanjavur medical college carcinoma stomach accounts to 11.4% of 
total cancer patients. 
 
Gastric cancer ranks third after breast and oral cavity malignancy. 
 
Out of 398 patients diagnosed as carcinoma stomach only 95 patients i.e. 
23.9% or one fourth underwent the possible curative resection (R0). 
 
This explains our patient’s unawareness and presenting in late stage and 
also the lack of screening programs in this area. 
 
Out of 95 patients undergoing curative resection the following 
observations were made 
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Most of the patients are above 40 years of age constituting about 55% which 
is comparable with other studies(5).The youngest was 29 yrs old female.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE NUMBER PERCENTAGE (%)
<20 0 0 
20-40 18 19 
41-60 53 55 
61-80 24 26 
>80 0 0 
TOTAL 95 100 
Sex wise distribution 
 
 
sex no PERCENTAGE (%)
MALE 63 66 
FEMALE 32 44 
TOTAL 95 100 
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Above 2/3 of patients in this study were males showing a ratio of 2:1 
In males gastric cancer ranks second to oral cavity malignancy. In females it 
ranks third to breast and oral cavity. 
 
 
 
 
 
Site of Tumor 
 
SITE NO PERCENTAGE (%) 
ANTRUM & PYLORUS 68 72 
BODY & MIDDLE 15 16 
GASTRO EOSPHAGEAL JUNCTION 6 6 
PROXIMAL & UPPER 6 6 
TOTAL 95 100 
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Growth antrum & pylorus is the most common site of carcinoma stomach in 
the study constituting about 72% comparable with other studies (4, 5). 
 
In gastro-esophageal junction type which accounts to 6%. Out of 6 patients 5 
belong to Siewert type III and one patient type II.All of these patients 
underwent CT of chest for staging. None of the patients belong to type I. 
 
One patient presented with Post Gastrojejunostomy stromal growth which was 
confirmed by Endoscopy and biopsy.  
 
In OGJ tumor type all patients had dysphagia as primary symptom. Vomiting 
and early satiety was the primary symptom in the rest of patients. 
 
50% of patients with antrum and pylorus growth had outlet obstruction either 
partial or total. 
 
H pylori association with proximal or upper tumors was not done in our study. 
 
 
 
 
 
 
Type of surgery – Gastrectomy performed 
 
 
 
 
 
 
 
 
 
 
 
TYPE OF SURGERY PERFORMED
PARTIAL 61%
UBTOTAL 22%
TOTAL 17%
PARTIAL
SUBTOTAL
TOTAL
 
 
 
 
 
SURGERY NO PERCENTAGE (%)
PARTIAL 58 61 
SUBTOTAL 21 22 
TOTAL 16 17 
TOTAL 95 100 
Partial gastrectomy was the most common surgery performed about 61%, giving 
proximal clearance of 5 to 6 cms and distal 2 cms, mostly for antrum and pylorus 
growth. 
In 16 patients undergoing total gastrectomy, 2 patients with proximal or upper 
growth also underwent spleenectomy.after resection all patients had Roux-en-Y 
oesophago jejunal anastomosis performed with either stapler or hand sewen method. 
In GEJ type i.e. 6 patients, all underwent total gastrectomy with resection of 
intraabdominal part of oesophagus after hiatal dissection and stapler anastomosis, 
Via abdominal approach 
Since none of patients had siewert type I and all patient’s with Type II variety 
underwent abdominal approach comparision of abdominal with combined thoracic 
approach was not compared and studied. 
3 patients with body or middle third growth underwent total gastrectomy. 
One patient with stromal growth following Truncal vagotomy and gastro-
jejunostomy also underwent total gastrectomy with Roux-en-Y anastomosis. 
Subtotal gastrectomy was done for all other i.e. 11 patient’s with body or middle 
growth. 
11 cases with antrum and pylorus growth also underwent subtotal gastrectomy. 
Standard method of procedure of dissection and anastomosis was followed in all 
cases. 
 
 
 
 
 
Depth of invasion 
 
DEPTH NO PERCENTAGE (%) 
MUCOSA 0 0 
SUBMUCOSA 2 2 
UPTO MUSCULARIS PROPRIA 36 38 
UPTO SEROSA 25 26 
SEROSA INVOLVED 32 34 
TOTAL 95 100 
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Although one of criteria for curative resection is serosa should not involved by the 
tumor, AJCC 2002 classify them into T3 and so they are potentially curable. 
Out of 95 cases in our study the following Pathological Tumor (T) stage was 
observed. 
Tumor Staging 
 
T stage No of cases
T1 2 
T2a 36 
T2b 25 
T3 32 
T4 0 
 
 
Only 2 cases fall into the early gastric cancer in the entire series of our study and in 
this one case had lymph node involved i.e. 50% in our series as compared to 18% in 
MSKCC series.   
98% fall in the either T2 or T3. 
 
34% of resected specimen had serosal involvement as compared to 60% in MSKCC 
series of 1221 cases. 
 
In cases with serosal involvement 87.5% had Lymph node involvement as compared 
to 68% in MSKCC series. 
16 out of  61 cases in T2 had lymph node involvement accounts to 26% as compare 
to 48 % in MSKCC series. (25, 26) 
Degree of differentiation 
 
DEGREE NO PERCENTAGE (%)
WELL 35 37 
MODERATE 37 39 
POOR 23 24 
TOTAL 95 100 
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Lauren’s classification which is the widely used one was not used in our study. 
According to Broder’s classification the degree of differentiation was analysed in our study 
A slight modification of the original nomogram designed by Kattan et al where Lauren’s 
classification was used was done using Broder’s classification. 
 In our centre WHO and Broder’s classification are followed by pathologist. 
 
 
Size of tumour in centimetres 
 
SIZE NO PERCENTAGE (%)
0-5  63 66 
6-10  23 24 
11-15 0 0 
16-20 0 0 
TOTAL 95 100 
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The largest one observed was 9.5 centimeters in size. 
Morphology rather than size plays a major role in determining the differentiation of tumor 
and prognosis as suggested by Bearzi and Ronalddi et al. (23)  
Nodal Staging 
 
Nodal status No of cases Percentage
NO 52 55 
N1 24 25 
N2 19 20 
N3 0 0 
 
As per AJCC classification the minimum no of lymph nodes that must be dissected and 
examined for proper nodal staging is 15.In our study the average no of lymph node 
examined per specimen is 5.The maximum being 10 lymph nodes. 
 
Number of nodes Positive 
 
Nodes  no PERCENTAGE (%)
NIL 52 55 
<5 24 26 
5-10 19 19 
11-15 0 0 
15-20 0 0 
TOTAL 95 100 
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Out of 45% of patients having positive lymph node 19% had more than 5 positive Lymph 
nodes. 
Patients with positive lymph node were given adjuvant chemotherapy consisting of 
5-Fluorouracil alone or a combination with mitomycin or cisplatin, 3 cycles at one month 
interval.  
All patients with more than 5 nodes positive were referred for adjuvant radiotherapy to 
gastric bed in addition to chemotherapy depending on general condition. 
 
 
Number of nodes negative 
 
NODES NO PERCENTAGE (%)
NIL 36 37 
<5 88 92 
6-10 1 1 
11-15 0 0 
16-20 0 0 
21-25 0 0 
TOTAL 95 100 
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When compared with other studies the average no of lymph nodes analysed in Japanese 
study is 62 per specimen where as it is 12 in MSKCC.In our centre it is on an average of 5 
lymph nodes per specimen. So Nodal staging is poor as minimum of 15 Lymph nodes 
should be removed and analysed for proper staging as per AJCC staging and guidelines. 
 
Study AVERAGE NO ANALYSED LN 
JAPANESE 62 
MSKCC 12 
PRESENT 5 
   
 
German studies suggest that ratio of positive nodes to negative nodes may be an 
independent prognostic index. As cady et al has well explained, resecting more lymph 
nodes does not alter survival, so resecting more negative nodes certainly will not. 
Comparative or randomised study of D1 verses D2 Lymphadenectomy was not done in our 
study as it has been well proved that D2 dissection does not alter overall survival in four 
separate RCT’s (67, 68, 69, and 70) 
In our institution only regional lymph node dissection depending on the site of tumor is 
done as routine  
 
 
TNM STAGING 
 
STAGE NO OF CASES PERCENTAGE
I 2 2 
II 47 50 
III 46 48 
IV 0 0 
 
 
98% of patients fall into Stage II and III in our study. 
 
 
 
 
 
 
Probability of 5 yrs survival as per Nomogram 
 
PRABABILITY NO PERCENTAGE (%)
<0.3 25 26 
0.3-0.5 10 10 
0.5-0.7 25 26 
0.7-0.8 21 22 
0.8-0.9 19 20 
>0.9 0 0 
TOTAL 95 100 
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Plotting the nomogram for all patients as per kattan et al the following observations were 
made. Nearly 64% of patients had survival probability greater than 0.5. 
This was used to for patient counselling, adjuvant therapy and follow up scheduling. 
  
 
 Survival after Curative Resection for Gastric Cancer by TNM Stage  
    Percentage (%) 
    T1 T2 T3 T4 
Study Number of Patients M SM MP US S S+ 
Noguchi et al (Japan)  3143 94 87 75 51 23  5 
Maruyama et al (Japan)  3176 95 87 82 65 34  14 
Boku et al (Japan)  238 — — 90 — 42  29 
Baba et al (Japan)  142 — — 55 — 34 32 
Hermanek (Germany)  977 84 75 73 40 24 25 
Shiu et al (United States)  246 — — 56 32 — 
Bozzetti et al (Italy)  361 82 69 38  — — 
MSKCC (United States)  944 91 56  26 — 
Our study 95 100 81 65 --- 
  
The survival depicted in the table shows till the present follow up which varies from 26 
months to 2 months. Long term follow up of 5 years is necessary to completely analyse and 
compare with other studies.   
 
Mortality and Morbidity 
 
Six of our patients expired in the post operative period. 
Three died due to duodenal stump blow out and other three due to other medical 
complications. 
Thirteen patients died in the follow up period of which 5 due to metastasis and others due 
to nutritional consequences and medical complications. 
Nearly 25 % of patients expired in the follow up till the end of study period 
All patients in the total gastrectomy category were given Vitamin B12 and Iron 
supplementation as routine. 
Those who developed other nutritional as well as mechanical complication were managed 
accordingly. 
Small stomach syndrome and afferent and efferent loop obstruction were the most common 
complication noted. 
Till end of study period nearly 60% patients are being followed up and counselled. 
All patients were advised monthly follow up with clinical examination. 
Ultrasonogram two monthly. 
Endoscopy was used in selected cases, suspicion of complication or recurrence. 
Computed Tomogram was also used  in selected cases. 
Recurrence Patterns after Primary Surgery for Gastric Cancer 
Author (Y) Analysis Local-Regional Peritoneal Distant 
Landry et al.29  
(1990)  
130 pts—
clinical 
38% (49/130) — — 
Gunderson and 
Sosin31 (1982)  
105 pts—
surgery 
69% (74/105) 42% 
(44/105) 
— 
Wisbeck100 
(1986)  
145 pts—
autopsy 
94% (15/16) 50% 
(8/16) 
44% liver, 
13% lung 
Roviello et al.95 
(2003)  
441 pts—first 
site of failure 
22%—lymph node, 11%; 
gastric bed/adjacent organs, 
8%; gastric stump, 3%  
17% 17% 
Allum et al.96 
(1989)  
145 pts—
clinical 
27% — 22% 
Our study 95 pts-clinical & 
investigation 
13% 6% -- 
 
45% of our patients underwent adjuvant chemotherapy and 13% along with radiotherapy to 
gastric bed. 
The recurrence pattern was studied and 12 patients developed loco regional recurrence and 
5 cases developed metastasis, all of them expired. 
Those who developed local recurrence, diagnosed and confirmed by investigations were 
referred for adjuvant Chemotherapy or if already completed chemotherapy, further 
additional two course of chemotherapy was given with combination of 5 Fluorouracil and 
mitomycin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
CONCLUSION 
 
 
Carcinoma Stomach is the third most common cancer in Thanjavur 
Medical College and Hospital. 
 
Males above 40 years are most commonly affected. 
 
Surgery is the only modality which offers cure. 
 
Curative gastrectomy (RO) offers a reasonable DSS. 
 
Mortality and morbidity of gastrectomy is high in our study. 
 
Most patients present in late stage of disease in our study. 
 
The extent of gastrectomy need not always be total and depends upon 
site of tumor. 
 
Extent of lymphadenectomy is controversy and need not always go for 
D2 resection. 
 Extent of lymphadenectomy depends on site of tumor and should 
strive to attain MSKCC level or AJCC standard. 
 
 
Nomogram is a good tool for predicting DSS and planning adjuvant 
therapy and counselling of patients which is accepted and followed in 
our centre. 
 
Adjuvant therapy increases the overall survival. 
 
Management of gastric cancer is a challenge and surgery offers a 
reasonable chance of survival in these patients. 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
S.No I.P.No Age Sex Surgery Site Type Size Depth N+ve N_ve DSS 
1 837031 42 M Subtotal A/P Well 3 3 0 3 0.81 
2 836155 60 M Partial A/P Mod 2 3 0 5 0.82 
3 840256 60 F Partial A/P Mod 4 4 0 0 0.73 
4 840201 50 M Subtotal A/P Well 3 4 0 5 0.72 
5 841117 50 F Partial A/P Poor 4 5 1 3 0.48 
6 845271 70 M Total+S B/M Well 7 5 4 4 0.20 
7 846791 42 M Subtotal A/P Well 4 4 1 0 0.53 
8 869033 40 F Total P/U Well 6 5 1 3 0.48 
9 869273 52 F Subtotal B/M Poor 6 3 2 2 0.58 
10 871549 60 F Total P/U Well 7 5 5 0 0.28 
11 873242 40 F Subtotal A/P Poor 6 4 0 5 0.60 
12 875260 52 M Subtotal B/M Poor 6 4 2 3 0.34 
13 875863 39 M Partial A/P Poor 4 4 0 5 0.35 
14 876484 40 F Partial A/P Poor 4 3 0 5 0.74 
15 875512 50 F Partial A/P Mod 4 3 0 6 0.84 
16 878463 46 F Partial A/P Well 4 3 0 3 0.82 
17 878487 48 F Total+S B/M Mod 5 4 0 3 0.61 
18 878355 50 M Partial A/P Well 4 3 0 2 0.84 
19 877787 42 F Partial A/P Poor 4 4 0 5 0.68 
20 879701 73 M Partial A/P Well 5 5 3 3 0.34 
21 877822 65 M Partial A/P Mod 4 4 3 5 0.50 
22 880589 45 M Partial A/P Mod 4 3 0 0 0.75 
23 881463 60 M Partial A/P Poor 4 5 3 0 0.30 
24 881477 29 M Subtotal A/P Poor 3 5 3 0 0.25 
25 881485 50 F Subtotal A/P Mod 3 3 0 0 0.78 
26 887291 60 M Subtotal B/M Poor 5 5 10 0 0.10 
27 887519 55 M Partial A/P Well 6 4 1 0 0.60 
28 886467 60 M Subtotal A/P Well 6 3 0 5 0.83 
29 889443 52 F Subtotal B/M Mod 6 4 0 5 0.64 
30 891797 45 F Partial A/P Mod 4 3 3 3 0.33 
31 891998 67 M Subtotal B/M Well 4 4 2 1 0.34 
32 900913 53 F Partial A/P Poor 4 5 0 2 0.55 
33 902180 54 M Subtotal A/P Mod 3 5 0 5 0.55 
34 901809 35 F Partial A/P Mod 3 5 0 5 0.55 
35 901283 60 M Partial A/P Well 3 5 3 0 0.32 
36 905086 70 F Partial A/P Mod 6 3 0 3 0.78 
37 905450 58 M Partial A/P Well 3 5 0 5 0.64 
38 906991 62 M Partial A/P Mod 4 3 0 0 0.76 
39 907217 30 F Subtotal B/M Mod 6 5 3 0 0.18 
40 908828 70 M Partial A/P Well 4 3 0 5 0.78 
41 908487 60 M Partial B/M Mod 4 5 5 0 0.18 
42 908691 30 M Partial A/P Well 3 2 0 5 0.88 
43 908622 53 M Partial B/M Mod 4 3 5 0 0.20 
44 911112 45 M Subtotal A/P Mod 6 5 5 0 0.09 
45 911503 42 M Partial A/P Well 3 3 0 5 0.79 
46 913644 40 M Partial A/P Mod 6 5 5 0 0.21 
47 916120 56 M Subtotal B/M Poor 6 5 5 0 0.15 
48 918631 45 M Partial A/P Mod 4 5 5 0 0.22 
49 920821 60 F Partial A/P Mod 4 4 0 5 0.79 
50 922224 40 F Subtotal B/M Well 6 2 5 0 0.60 
51 922616 58 F Partial A/P Well 3 3 3 2 0.66 
52 922651 65 M Total OGJ Mod 6 3 0 3 0.64 
53 924146 38 F Partial A/P Well 3 4 2 3 0.52 
54 924065 45 M Partial A/P Well 4 3 0 3 0.80 
55 925595 50 M Partial A/P Mod 4 3 0 3 0.77 
56 926172 52 M Partial A/P Poor 4 4 2 2 0.34 
57 927521 65 M Partial A/P Mod 4 3 0 3 0.74 
58 926960 40 M Partial A/P Poor 4 3 0 5 0.72 
59 929601 52 M Partial A/P Poor 4 5 5 0 0.21 
60 929364 68 M Partial A/P Well 4 3 0 3 0.78 
61 929157 45 F Total PGJ Mod 3 4 0 0 0.65 
62 929315 67 M Total P/U Mod 8 5 5 0 0.06 
63 929453 50 F Total OGJ Mod 6 4 0 5 0.66 
64 929200 68 M Subtotal B/M Poor 8 3 5 0 0.24 
65 928492 55 F Partial A/P Mod 3 3 0 0 0.82 
66 929454 45 F Total P/U Poor 8 5 5 0 0.07 
67 933751 51 M Partial A/P Well 4 4 1 4 0.60 
68 933284 60 M Partial A/P Poor 4 4 1 4 0.58 
69 933758 62 M Partial A/P Mod 3 3 0 5 0.80 
70 934018 35 M Partial A/P Mod 4 3 0 5 0.75 
71 936241 63 M Total OGJ Well 8 4 0 10 0.65 
72 934088 55 M Partial A/P Mod 6 5 8 0 0.06 
73 938341 60 F Total OGJ Mod 8 5 5 5 0.25 
74 938600 57 M Partial A/P Well 4 3 0 3 0.84 
75 935303 50 M Partial A/P Well 4 3 0 2 0.82 
76 934114 40 M Total OGJ Poor 8 5 8 0 0.03 
77 940915 40 F Partial A/P Well 2 5 5 0 0.25 
78 941860 50 F Partial A/P Well 4 3 0 3 0.81 
79 938776 63 M Subtotal A/P Mod 6 5 3 3 0.26 
80 943261 31 F Partial A/P Mod 4 3 0 5 0.78 
81 944628 45 M Total OGJ Poor 3 3 0 5 0.72 
82 946502 60 M Partial A/P Mod 4 3 0 3 0.84 
83 945052 47 M Subtotal B/M Well 8 5 5 0 0.20 
84 947136 43 M Partial A/P Well 4 3 0 3 0.78 
85 946648 51 M Subtotal A/P Well 4 4 0 5 0.67 
86 948069 40 F Partial A/P Well 4 3 0 3 0.82 
87 948402 40 M Partial A/P Poor 4 5 10 0 0.04 
88 948060 54 M Subtotal A/P Mod 5 4 0 5 0.64 
89 948018 55 M Total P/U Well 8 3 0 3 0.73 
90 950438 55 F Partial A/P Well 4 3 0 3 0.84 
91 949108 60 M Partial A/P Well 4 4 0 5 0.72 
92 952590 64 M Partial A/P Poor 4 4 1 4 0.55 
93 951440 52 M Subtotal B/M Poor 6 5 4 1 0.23 
94 954545 60 M Partial A/P Mod 4 4 5 0 0.26 
95 952248 62 M Total P/U Mod 7 5 6 0 0.22 
 
 
 
 
 
PROFORMA 
 
 
 
 
 
 
CASE PROFORMA 
 
NAME: 
 
AGE: 
 
SEX: 
 
IP NUMBER: 
 
UNIT: 
 
DATE OF ADMISSION: 
DATE OF SURGERY: 
DATE OF DISCHARGE: 
 
COMPLAINTS: 
 
 
GENERAL EXAMINATION: 
 
BP:                    PR:            GENERAL CONDITION: 
 
SYSTEMIC EXAMINATION: 
ABDOMEN 
                 MASS 
                 VGP 
   FREE FLUID 
   STATUS OF LIVER 
   PR & PV 
INVESTIGATIONS: 
 
ROUTINE BLOOD TESTS: 
BLOOD GROUP: 
X-RAY CHEST: 
CONTRAST STUDIES: 
UGI SCOPY & BIOPSY: 
USG ABDOMEN: 
CT ABDOMEM: 
DIAGNOSTIC LAPROSCOPY: 
 
ANAESTHETIC ASSESMENT: 
 
SURGERY PERFORMED: 
 
COMPLICATION: 
 
PATHOLOGICAL SPECIMEN ANALYSIS: 
1)PRIMARY SITE: 
2)TYPE & DIFFERENTATION: 
3)SIZE OF TUMOR: 
4)DEPTH OF INVASION: 
5)NO OF POSITIVE LYMPHNODES: 
6)NO OF NEGATIVE LYMPHNODES: 
7)PROXIMAL & DISTAL MARGINS: 
 
NORMOGRAM FOR DISEASE SPECIFIC SURVIVAL: 
 
ADJUVANT THERAPY: 
 
FOLLOW UP: 
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NOMOGRAM 
 
 
 
 
 
Nomogram for disease-specific survival (DSS). Instructions for physician: Locate the 
patient's sex on the Sex axis. Draw a line straight upward to the Points axis to determine 
how many points toward gastric cancer–specific death the patient received for his or her 
sex. Sum the points achieved for each predictor, and locate this sum on the Total Points 
axis. Draw a line straight down to the disease-specific survival axes to find the patient's 
probability of surviving gastric cancer, assuming he or she does not die of another cause 
first. A/P, antrum or pyloric; B/M, body or middle one-third, Dif, diffuse; GEJ, 
gastroesophageal junction; int, intestinal; mix, mixed; NumPosNodes, number of positive 
nodes; NumNegNodes, number of negative nodes; Prob.; probability; P/U, proximal or 
upper one-third. 
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Pattern of Nodal Metastases from Gastric Cancer 
  Upper Third (%) Middle Third (%) Lower Third (%) 
Paracardia 22 9 4 
Lesser or greater curvature 25 36 37 
Right gastric artery/ suprapyloric 2 3 12 
Infrapyloric 3 15 49 
Left gastric artery 19 22 23 
Common hepatic artery 7 11 25 
Celiac axis 13 8 13 
Splenic artery/hilum 11 3 2 
Hepatoduodenal ligament 1 2 8 
Others 0–5 0–5 0–5 
 
 
LYMPHNODE  STATION 
 
 
 
 
 
Definition of American Joint Committee on Cancer/International Union Against Cancer 
T stage based on depth of penetration of the gastric wall. 
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